Hypertension and cardiac arrhythmias: A review of the epidemiology, pathophysiology and clinical implications

Journal of Human Hypertension

Volumn 22, Issue 6, 2008, Pages 380-388

  Yiu, K H ^a   Tse, H F ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMIODARONE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 6; IRBESARTAN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; REACTIVE OXYGEN METABOLITE; THIAZIDE DIURETIC AGENT; THROMBIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALSARTAN; VASOPRESSIN;

ANTIINFLAMMATORY ACTIVITY; ARRHYTHMOGENESIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; ESSENTIAL HYPERTENSION; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOKALEMIA; INCIDENCE; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; HEMODYNAMICS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 44149094528     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.10     Document Type: Review

References (92)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke pevention: The AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
4. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006; 27: 949-953.
5. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110: 1042-1046.
6. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-844.
7. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-2461.
8. kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82(Suppl 1): 2N-9N.
9. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F et al. Atrial fibrillation in hypertension: Predictors and outcome. Hypertension 2003; 41: 218-223.
10. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
11. Olsson SB, Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randoinised controlled trial. Lancet 2003; 362: 1691-1698.
12. Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77: 18-22.
13. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 1987; 60: 560-565.
14. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317: 787-792.
15. Ferrara N, Furgi G, Longobardi G, Nicolino A, Acanfora D, Leosco D et al. Relation between age, left ventricular mass and ventricular arrhythmias in patients with hypertension. J Hum Hypertens 1995; 9: 581-587.
16. Cupples LA, Gagnon DR, Kannel WB. Long- and short-term risk of sudden coronary death. Circulation 1992; 85(1 Suppl): I11-I18.
17. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32: 1454-1459.
18. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular, hypertrophy. J Am Coll Cardiol 1993; 22: 1111-1116.
19. Kowey PR, Friechling TD, Sewter J, Wu Y, Sokil A, Paul J et al. Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation 1991; 83 2067-2075.
20. Vester EG, Kuhls S, Ochiulet-Vester J, Vogt M, Strauer BE. Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension. Eur Heart J 1992; 13(Suppl D): 70-81.
21. Wright J, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev 2007; e-pub ahead of print 7 November 2007.
22. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cordiol 2000; 35: 1669-1677.
23. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: Regulation, signalling and function. Blood Press 2003; 12: 70-88.
24. Rogg H, de Gasparo M, Graedel E, Stulz P, Burkart F, Eberhard M et al Angiotensin II-receptor subtypes in humam atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J 1996; 17: 1112-1120.
25. Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G et al Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003; 42: 1785-1792.
26. Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JG et al. Regulation of, angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678-2681.
27. Yano M, Kim S, Izumi Y, Yamanaka S, Iwao H. Differential activation of cardiac c-Jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II mediated hypertension. Circ Res 1998; 83: 752-760.
28. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-2614.
29. Choisy SCM, Arberry LA, Hancox JC, James AF. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension 2007; 49: 498-505.
30. Wijffels MC, Kirchhof CJ, Dorland R, Allessie. MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
31. Nakashima H, Kumagai K, Urata H, Gonda N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
32. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa. K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41 2197-2204.
33. Marrero MB, Paxton WG, Duff JL, Berk BC, Bernstein KE. Angiotensin II stimulates tyrosine phosphorylation of phospholipase C-gamma 1 in vascular smooth muscle cells. J Biol Chem 1994; 269: 10935-10939.
34. Griendling KK, Rittenhouse SE, Brock TA, Ekstein LS, Gimbrone MA et al. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem 1986; 261: 5901-5906.
35. Engelmann MD, Svendsen JH. Inflammation in tha genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-2092.
36. Brasier AR, Recinos III. A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-1266.
37. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez Ubago JL et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-291.
38. Lorell BH, Carabello BA. Left ventricular hypertrophy: Pathogenesis, detection, and prognosis. Circulation 2000; 102: 470-479.
39. Weber KT. Targeting pathological remodeling: Concepts of cardioprotection and reparation. Circulation 2000; 102: 1342-1345.
40. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventriculhr hypertrophy. Am Heart J 2001; 141: 334-341.
41. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Risks for atrial fibrillation and congestive heart failure in patients ≥65 years of age with abnormal left ventricular diastolic relaxation. Am J Cardiol 2004; 93: 54-58.
42. Tsang TS, Gensh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR et al Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002; 40: 1636-1644.
43. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension 1995; 25: 1155-1160.
44. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997; 90: 1686-1695.
45. Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 833-842.
46. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108: 7-13.
47. Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovusc Res 1994; 28: 933-946.
48. Savelieva I, Yap YG, Yi G, Guo XH, Hnatkova K, Camm AJ et al. Relation of ventricular repolarization to cardiac cycle length in normal subjects, hypertrophic cardiomyopathy, and patients with myocardial infarction. Clin Cardiol 1999; 22: 649-654.
49. Davey PP, Bateman J, Mulligan IP, Forfar C, Barlow C, Hart G. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: Relation to autonomic nervous system and Holter tape abnormalities. Heart 1994; 71: 268-273.
50. Matsumura K, Takata Y, Ansai T, Awano S, Takehara T, Fujii K et al Association of QT interval with blood pressure in 80-year-old subjects. Hypertens Res 2004; 27: 387-391.
51. Tribulova N, Okruhlicova L, Novakova S, Pancza D, Bernatova I, Pechanova O et al. Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)induced lethal arrhythmias in isolated rat heart. Exp Physiol 2002; 87: 195-205.
52. 2+ handling and vulnerability to ventricular fibrillation in spontaneously hypertensive rats. Hypertension 1997; 30: 461-467.
53. Ohtsuka S, Kakihana M, Watanabe H, Enomoto T, Ajisaka R, Sugishita Y. Alterations in left ventricular wall stress and coronary circulation in patients with isolated systolic hypertension. J Hypertens 1996; 14: 1349-1355.
54. Burke AP, Farb A, Liang YH, Smialek J, Virmani R. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation 1996; 94: 3138-3145.
55. Erdogan D, Yildirim I, Ciftci O, Ozer I, Caliskan M, Gullu H et al Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function. Circulation 2007; 115: 593-599.
56. Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res 1999; 42: 27-44.
57. Müller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol. (SILVHIA). J Hypertens 2007; 25: 1958-1966.
58. Mancia G, Chalmers G, Ferrari A, Julius S, Saruta T, Weber M (eds). Etiology and pathophysiology of hypertension: Neural factors. Manual of Hypertension 2002.
59. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992; 85: 177-197.
60. Barron HV, Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 1996; 27: 1053-1060.
61. Harrap SB, Mitchell GA, Casley DJ, Mirakian C, Doyle AE. Angiotensin II, sodium, and cardiovascular hypertrophy in spontaneously hypertensive rats. Hypertension 1993; 21: 50-55.
62. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Cardiol 2003; 115: 41-46.
63. Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K et al Progressive hypertrophy regression with sustained pressure reduction in hypertension: The Losartan Intervention For Endpoint Reduction study. J Hypertens 2002; 20: 1445-1450.
64. Manolis AJ, Beldekos D, Handanis S, Haralabidis G, Hatzissavas J, Foussas S et al. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. Am J Hypertens 1998; 11: 640-648.
65. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventrricular mass in mild to moderate hypertension: Comparison of six antihypertensive agents. Circulation 1997; 95: 2007-2014.
66. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993; 27 341-348.
67. Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlof B et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105 1071-1076.
68. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54: 456-461.
69. Choudbury A, Varughese GI, Lip GY. Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: A shift from electrical to structural therapy? Expert Opin Pharmacother 2005; 6: 2193-2207.
70. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44: 159-164.
71. Schmieder R, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua T et al. Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial. J Hypertens 2006; 24: S3.
72. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006; 296: 1242-1248.
73. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B et al Angiotensin II receptor blockade reduces new-onset atrial fibrillation, and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
74. Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E et al Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006; 47: 46-50.
75. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
76. Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG et al. Rationale and design of the GISSI-Atrial Fibrillation Trial: A randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med (Hagerstown) 2006; 7: 29-38.
77. Irbesartan for the prevention of atrial arrhythmias and cardiac electrical remodeling in patients with hypertension and permanent pacemakers. NCT002255667; 002252006: http://www.clinicaltrials.gov/.
78. The ASC. Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J 2006; 151: 1187-1193.
79. Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T et al. Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension. Circ J 2006; 70: 1318-1321.
80. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52-61.
81. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
82. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
83. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690-1696.
84. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000; 356: 1789-1794.
85. Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007; 370: 604-618.
86. Yurenev AP, Dyakonova HG, Novikov ID, Vitols A, Pahl L, Haynemann G et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992; 5: 182S-189S.
87. Wachtell K, Okin PM, Olsen MH, Dahlof B, Devereux RB, Ibsen H et al Regression of electro-cardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007; 116: 700-705.
88. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997; 80: 35J-39J.
89. Egan BM, Basile J, Chilton RJ, Cohen JD. Cardioprotection: The role of beta-blocker therapy. J Clin Hypertens (Greenwich) 2005; 7: 409-416.
90. Hoes AW, Grobbee DE, Lubsen J. Sudden cardiac death in patients with hypertension. An association with diuretics and beta-blockers? Drug Saf 1997; 16: 233-241.
91. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-1857.
92. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension 2008; 51: 393-398.